InMed Pharmaceuticals Inc (INM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, InMed Pharmaceuticals Inc (INM) has a cash flow conversion efficiency ratio of 0.000x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.76 Million) by net assets ($6.89 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See INM days of operational coverage to measure how many days the company can operate on defensive assets alone.
InMed Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2001–2025)
This chart illustrates how InMed Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
InMed Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of InMed Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Young & Co.'s Brewery P.L.C
LSE:YNGN
|
0.064x |
|
Keystone Law Group PLC
LSE:KEYS
|
0.375x |
|
Direct Digital Holdings Inc
NASDAQ:DRCT
|
0.108x |
|
Brown Advisory US Smaller Companies PLC
LSE:BASC
|
-0.002x |
|
ELEMENT NUTR.SCIENCES
F:93X
|
0.014x |
|
Aker Carbon Capture ASA
OL:ACC
|
-0.772x |
|
Elixinol Wellness Ltd
AU:EXL
|
-0.246x |
|
Jiuzi Holdings Inc
NASDAQ:JZXN
|
-0.105x |
Annual Cash Flow Conversion Efficiency for InMed Pharmaceuticals Inc (2001–2025)
The table below shows the annual cash flow conversion efficiency of InMed Pharmaceuticals Inc from 2001 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of InMed Pharmaceuticals Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | $18.30 Million | $-7.77 Million | -0.424x | +23.52% |
| 2024-06-30 | $12.59 Million | $-6.99 Million | -0.555x | -22.01% |
| 2023-06-30 | $16.02 Million | $-7.28 Million | -0.455x | +65.89% |
| 2022-06-30 | $11.69 Million | $-15.58 Million | -1.333x | -24.22% |
| 2021-06-30 | $9.12 Million | $-9.79 Million | -1.073x | +14.46% |
| 2020-06-30 | $5.88 Million | $-7.37 Million | -1.255x | -160.77% |
| 2019-06-30 | $13.88 Million | $-6.68 Million | -0.481x | -169.76% |
| 2018-06-30 | $20.62 Million | $-3.68 Million | -0.178x | +53.82% |
| 2017-06-30 | $6.13 Million | $-2.37 Million | -0.386x | +17.93% |
| 2016-06-30 | $820.48K | $-386.07K | -0.471x | +62.66% |
| 2015-06-30 | $1.28 Million | $-1.61 Million | -1.260x | -198.64% |
| 2014-06-30 | $1.52 Million | $-641.38K | -0.422x | -147.41% |
| 2013-06-30 | $-44.11K | $-39.26K | 0.890x | +101.38% |
| 2012-06-30 | $2.72K | $-174.62K | -64.269x | -2213.15% |
| 2011-06-30 | $202.29K | $-562.06K | -2.778x | -1721.34% |
| 2010-06-30 | $-1.14 Million | $-195.42K | 0.171x | +275.50% |
| 2009-06-30 | $-1.03 Million | $100.48K | -0.098x | -101.43% |
| 2008-06-30 | $-138.98K | $-951.15K | 6.844x | +366.18% |
| 2007-06-30 | $-950.42K | $-1.40 Million | 1.468x | +23.41% |
| 2006-06-30 | $-485.38K | $-577.40K | 1.190x | +13.61% |
| 2005-06-30 | $-670.63K | $-702.23K | 1.047x | -49.06% |
| 2004-06-30 | $-235.55K | $-484.19K | 2.056x | +158.86% |
| 2003-06-30 | $241.85K | $-844.62K | -3.492x | -293.57% |
| 2002-06-30 | $1.29 Million | $-1.14 Million | -0.887x | -686.17% |
| 2001-06-30 | $4.18 Million | $-471.69K | -0.113x | -- |
About InMed Pharmaceuticals Inc
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States. The company operates through two segments, InMed Pharmaceuticals and BayMedica Commercial. The InMed Pharmaceuticals segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica Commercial segment develops proprietary manufactur… Read more